Patents and Licensing
We offer Charité and BIH employees advice and support on all aspects of intellectual property (property rights, know-how, material, data, software) and its commercialization. In addition, we provide information about funding for spin-off projects and accompany all start-ups at Charité during the founding phase.
We help external institutions and companies to find and license suitable technology offers.
For an efficient technology transfer, we cooperate with the external service provider Ascenion to evaluate and market the intellectual property of Charité and BIH.
If you have any questions, please do not hesitate to contact us. We will be happy to advise you!
Services for employees at BIH and Charité
- Search for innovative ideas, e.g. via our Idea Office
- Evaluation of IP (intellectual property such as know-how, data, material, software) as well as consulting regarding the protection (patenting) and commercialization of IP
- Licensing of IP - negotiation and granting of rights of use
- Business development for translational projects
- Support for the spin-off of start-ups at Charité/BIH incl. participation of our partner Ascenion on behalf of Charité
- Advice on start-up and public funding opportunities for spin-offs from the scientific community
- Review, negotiation and signing of Material Transfer Agreements (MTAs)
- Forms and templates: e.g. invention disclosures and software disclosures (please download the document to open it)
Services for externals
Technology Offers
You can find an overview of our technology offers on the website of our technology transfer service provider Ascenion GmbH. Please visit this page and select Charité - Universitätsmedizin Berlin as the "Institute of Origin".
Please feel free to contact us if you are interested.
Patent or publication? Best hand in hand!
Many scientists think that publishing and patenting are mutually exclusive. However, patenting IP (intellectual property) is the best way to make the findings available to as many patients as possible.
Without patenting a technology, it will not reach patients in mainstream care. This is because external companies can only license protected(!) intellectual property in the translational process and otherwise are not given an incentive to develop the technology to market readiness.
If you are currently involved in a publication, remember to contact us early on for protection of your intellectual eIgent. Please feel free to book a free and confidential consultation at our Idea Office - together we can generate more impact out of your idea.
| 190 | translational projects |
| 502 | patents |
| 141 | patent families |
| 27 | supported start-ups |
| 70 | annual invention disclosures |
| 7 Mio. € | annual revenues |
![[Translate to englisch:]](/fileadmin/_processed_/7/4/csm_Claudia_Keil-Dieckmann_4422_II_e27c9e4e9e.jpg)